Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transferrin receptor protein 1 (TfR1), also known as CD71, is a type II transmembrane glycoprotein that functions as a homodimer to mediate cellular iron uptake. It binds diferric transferrin and internalizes it through clathrin-mediated endocytosis. TfR1 is essential for supplying iron to cells, particularly rapidly dividing cells like erythroid precursors. Its expression is tightly controlled by intracellular iron levels. TfR1 is highly upregulated on rapidly proliferating cells, including many cancer types, making it a target for cancer therapy. Antibodies targeting TfR1 can be used as direct anti-cancer agents or as drug delivery vehicles.
Monoclonal antibodies against TfR1/CD71 block its function or deliver cytotoxic agents into cancer cells. Antibodies may act directly (by inhibiting receptor function or triggering immune effector mechanisms like ADCC/CDC) or indirectly as delivery vehicles for drugs/toxins/nucleic acids into tumor cells due to efficient internalization properties.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transferrin receptor protein 1 (TfR1).